FOR LABORATORY RESEARCH PURPOSES ONLY. This compound has not received FDA approval. All information shown is drawn from published laboratory research for educational purposes
$50.00
Lost, stolen, or damaged? We replace it, on us.
Pick your speed at checkout.
Before you continue
This site sells research products exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.
Semax is a synthetic peptide developed from a fragment of adrenocorticotropic hormone (ACTH), supplied by Peppy Peptides for laboratory research use only. It is a well-characterized compound for controlled neurochemical-signaling research.
Semax is derived from a fragment of ACTH and modified with additional amino acids for greater stability in research settings. It belongs to the class of ACTH-fragment analogues that researchers study in relation to neurotrophic signaling systems.
Laboratory research has examined how Semax interacts with brain-derived neurotrophic factor (BDNF) expression pathways and with monoaminergic signaling in cell-based and animal-model systems. Because Semax is structurally distinct from native ACTH, it is studied separately as a peptide of interest in neuroscience research.
Semax is referenced in laboratory literature on neurotrophic-signaling pathways, particularly BDNF expression in cell-culture and animal-model systems. Researchers also study its interaction with dopaminergic and serotonergic signaling in vitro.
Neuroscience laboratories have used Semax as a reference compound in models of synaptic-signaling and neuronal-survival pathways. Published research has also examined its interaction with oxidative-stress response pathways in neuronal cell models. As an ACTH-fragment analogue, Semax also appears in structure-activity research comparing modified and native ACTH-derived peptides.
Semax is studied for its interaction with neurotrophic (BDNF-related) and monoaminergic signaling pathways in cell-based and animal-model systems.
Semax is a synthetic analogue built on a fragment of adrenocorticotropic hormone and extended with additional amino acids. Because it is structurally distinct from the native hormone, it is studied as a separate research peptide.
Published laboratory research on Semax is indexed on PubMed.
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. This compound has not received FDA approval. All information shown is drawn from clinical studies for educational purposes.
Researcher favourites
Price range: $125.00 through $175.00
Price range: $150.00 through $650.00
Price range: $125.00 through $700.00
$150.00
$175.00
Lab-verified quality
Each lot is analysed by Bioviridian before release. Below is the Certificate of Analysis for the most recent lot, as issued by the laboratory.
Overall purity
99.7%
RP-HPLC (214 nm)
View the signed COA (PDF)Check this certificate at bioviridians.com/coa-search.html with code COA7698.
Test results
5 of 5 conformHPLC retention time 9.324 min · Signed: Shane Straight, M.S., Principal Chemist, Bioviridian Inc.
Every lot keeps its own signed certificate. Lots are listed newest first.
Lot SEMAX072026-MG
99.7%
Overall purity
Tested July 13, 2026
Open COAEarlier lots will appear here as new Certificates of Analysis are published.
Compound details
Molecular profile
Storage requirements
Supplied lyophilized; store at −20°C for long-term stability; avoid repeated freeze-thaw cycles
Refrigerate at 2–8°C after reconstitution; use within 4–6 weeks
Published literature
4 peer-reviewed publications indexed on PubMed. Listed for reference only; inclusion does not imply any use, effect or endorsement.
BRAIN RES · 2006
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108
Measured BDNF and TrkB receptor expression in the rat hippocampus following Semax administration.
J NEUROCHEM · 2006
Dolotov OV, Karpenko EA, Seredenina TS, et al. J Neurochem. 2006;97 Suppl 1:82-6. doi:10.1111/j.1471-4159.2006.03658.x
Characterised specific binding of radiolabelled Semax in rat basal forebrain and measured local BDNF protein levels.
BMC GENOMICS · 2014
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228
Used genome-wide transcriptional analysis to profile gene-expression changes in rat brain after focal ischemia with and without Semax.
CELL MOL NEUROBIOL · 2010
Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Cell Mol Neurobiol. 2010;30(1):71-9. doi:10.1007/s10571-009-9432-0
Examined transcription of neurotrophin and neurotrophin-receptor genes in rat brain after experimental cerebral ischemia in the presence of Semax or Pro-Gly-Pro.
